Timely Genetic Testing and Therapy Management in Patients With gBRCA-Mutated Metastatic Breast Cancer Receiving...

Area of Science:

• Oncology
• Medical Genetics
• Pharmacology

Background:

• Talazoparib is an effective poly(ADP-ribose) polymerase (PARP) inhibitor for germline BRCA1/2 (gBRCA1/2)-mutated, HER2-negative, locally advanced or metastatic breast cancer (mBC).
• NCCN guidelines recommend genetic testing for metastatic breast cancer patients to identify gBRCA1/2 mutations for PARP inhibitor eligibility.
• Many eligible patients do not undergo genetic testing due to various barriers.

Purpose of the Study:

• To highlight the crucial role of advanced practitioners (APs) in facilitating genetic testing for mBC patients.
• To provide practical guidance on utilizing talazoparib, including managing adverse events and drug interactions.
• To illustrate genetic testing strategies and treatment considerations with talazoparib through a hypothetical case study.

Main Methods:

• Review of talazoparib's efficacy and safety data from the EMBRACA and ABRAZO trials.
• Presentation of a hypothetical case study of a 42-year-old woman with triple-negative mBC.
• Discussion of genetic testing pathways and treatment management for APs.

Main Results:

• Talazoparib demonstrates strong efficacy with manageable side effects in patients with gBRCA1/2-mutated mBC.
• APs can significantly impact patient care by navigating the genetic testing process and informing treatment decisions.
• The case study provides a practical framework for APs to implement genetic testing and talazoparib therapy.

Conclusions:

• Genetic testing is essential for identifying patients with gBRCA1/2 mutations who can benefit from PARP inhibitors like talazoparib.
• APs are pivotal in overcoming barriers to genetic testing and optimizing talazoparib treatment for mBC.
• Effective management of talazoparib, including adverse events and drug interactions, is key to improving patient outcomes.